MENU
+Compare
LVRLF
Stock ticker: OTC
AS OF
Aug 15 closing price
Price
$0.06
Change
+$0.01 (+20.00%)
Capitalization
6.56M

LVRLF stock forecast, quote, news & analysis

CordovaCann Corp is a Canadian-domiciled company focused on building a diversified cannabis company... Show more

LVRLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for LVRLF with price predictions
Aug 15, 2025

LVRLF in upward trend: price rose above 50-day moving average on August 12, 2025

LVRLF moved above its 50-day moving average on August 12, 2025 date and that indicates a change from a downward trend to an upward trend. In of 59 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on LVRLF as a result. In of 150 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LVRLF just turned positive on July 15, 2025. Looking at past instances where LVRLF's MACD turned positive, the stock continued to rise in of 72 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for LVRLF crossed bullishly above the 50-day moving average on August 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where LVRLF advanced for three days, in of 125 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 81 cases where LVRLF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The 50-day moving average for LVRLF moved below the 200-day moving average on July 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

LVRLF broke above its upper Bollinger Band on July 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LVRLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.657). P/E Ratio (0.000) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.696). LVRLF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.652) is also within normal values, averaging (40.190).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LVRLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.75B. The market cap for tickers in the group ranges from 5.57K to 68.3B. ZTS holds the highest valuation in this group at 68.3B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 78%. CANN experienced the highest price growth at 160%, while INNPF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -30%. For the same stocks of the Industry, the average monthly volume growth was -38% and the average quarterly volume growth was 99%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 68
Price Growth Rating: 55
SMR Rating: 83
Profit Risk Rating: 92
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
LVRLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
217 Queen Street West
Phone
+1 416 523-3350
Employees
N/A
Web
https://www.cordovacann.com